The FDA has granted full approval to Laverdia (verdinexor tablets) for treating dogs with lymphoma, marking a significant milestone for pet owners battling one of the most common canine cancers.
The approval, announced by the FDA, upgrades the medication’s status from its original conditional approval granted in January 2021. Developed by Anivive Lifesciences, Laverdia represents a major advancement in canine cancer treatment as an oral tablet that can be administered at home.
From Conditional to Full Approval
When the FDA initially approved Laverdia-CA1 conditionally in 2021, it did so through the Minor Use/Minor Species pathway, as canine lymphoma affects fewer than 70,000 dogs annually in the United States. The conditional status could have been renewed for up to four one-year periods, but the drug’s effectiveness data has now warranted full approval ahead of that timeline.
“This increases the amount of drug absorbed into the bloodstream,” noted the FDA in their statement about the medication’s formulation and effectiveness.
What makes this approval particularly notable for veterinarians and pet owners alike? Unlike traditional lymphoma treatments that often require frequent visits to veterinary clinics for injections or infusions, Laverdia can be administered twice weekly by pet owners in their homes, potentially reducing stress for both dogs and their families during an already difficult time.
Promising Efficacy Data
The clinical performance of verdinexor has been encouraging. Pamela D. Jones, DVM, DACVIM (Oncology), DACVR (Radiation Oncology), reports that the drug has shown a 37% overall response rate in canine lymphoma. Perhaps more importantly, Dr. Jones notes that verdinexor “has not been shown to cause resistance to other chemotherapy types,” preserving future treatment options.
This characteristic could be crucial for managing lymphoma, which often requires multiple treatment approaches over time as the disease progresses or relapses.
Laverdia works differently than traditional chemotherapy. The medication is classified as a selective inhibitor of nuclear export (SINE), which means it blocks certain proteins from leaving the cell nucleus, ultimately leading to the death of cancer cells while potentially sparing healthy ones.
Home Administration Advantages
The at-home oral administration represents a significant quality-of-life improvement for canine patients. Traditional lymphoma protocols typically involve weekly visits to specialty veterinary clinics for injections and intensive monitoring.
Veterinarians at Salish Veterinary Group highlight that Laverdia-CA1’s twice-weekly oral dosing schedule can be managed by owners, potentially reducing the stress associated with frequent veterinary visits.
Still, veterinary oversight remains essential. The drug is available by prescription only, and regular check-ups are necessary to monitor response and potential side effects. VCA Animal Hospitals caution that verdinexor is approved specifically for canine lymphoma, and any off-label use is not permitted under FDA guidelines.
For the thousands of dog owners who receive the devastating diagnosis of lymphoma each year, Laverdia’s full approval offers not just a new treatment option, but something equally valuable in the cancer journey: convenience during an inconvenient time, and a bit more normalcy during what is anything but a normal experience.
